Teva to restart production of cancer drug after shortages stressed treatment
Vincristine is the latest example of an essential drug for which supplies have run short, with few or no manufacturers available to take up production.
Shortages of the generic bladder cancer therapy BCG or Takeda’s thyroid medication Natpara, to name two recent examples, have stressed treatment and put patients in the difficult position of seeking out less effective alternatives or rationing available medicine.
